drugset / Trial / NCT05866432
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2026-05-23
- Completion
- 2026-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Datopotamab deruxtecan | Monoclonal antibody | 6 mg/kg | Intravenous |